Jansitin Duo

Metformin Hydrochloride and Sitagliptin, the active ingredients in Jansitin Duo, are a biguanide and DPP‑4 inhibitor presented as an oral tablet for adult use. They treat type 2 diabetes mellitus in patients who need combined glucose‑lowering therapy.

GNH USA supplies Jansitin Duo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Jansitin Duo is used in the management of type 2 diabetes mellitus, a chronic metabolic disorder requiring glycaemic control. - Type 2 diabetes mellitus: improves overall glycaemic control and reduces HbA1c. - In combination with diet and exercise: helps patients achieve target blood‑glucose levels. - When added to metformin monotherapy: provides additional reduction in fasting plasma glucose.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhoea: frequent loose stools, usually transient. - Abdominal discomfort: cramps or bloating. - Headache: mild tension‑type headache. - Upper respiratory tract infection: nasopharyngitis symptoms. - Hypoglycaemia (when combined with insulin or sulfonylureas): dizziness or sweating.

Serious or Rare Side Effects: - Lactic acidosis: severe metabolic acidosis, potentially fatal. - Pancreatitis: acute abdominal pain with elevated enzymes. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic failure: jaundice, elevated liver enzymes. - Anaphylaxis: rapid onset of airway swelling and hypotension. - Renal impairment: worsening kidney function, especially in dehydration.

Before initiating Jansitin Duo, clinicians should evaluate patient-specific factors and monitor for adverse events. - Renal function: assess baseline eGFR and monitor periodically. - Lactic acidosis risk: avoid in patients with severe renal or hepatic impairment. - Hypoglycaemia: monitor closely if used with insulin or sulfonylureas. - Pregnancy and lactation: prescribe only if benefits outweigh potential risks. - Drug interactions: review concomitant medications for possible interactions. - Store at ambient temperature: keep below 25°C, retain original packaging, protect from moisture.

Jansitin Duo may interact with several medicines, requiring careful management. Major Interactions (Avoid): - Phenformin: co‑administration is contraindicated due to heightened lactic acidosis risk. - Severe renal impairment (eGFR <30 mL/min/1.73 m²): increased metformin accumulation. Moderate Interactions (Monitor Closely): - Sulfonylureas or insulin: heightened risk of hypoglycaemia. - Iodinated contrast agents: temporary renal function decline may necessitate drug interruption. - Cimetidine: may increase sitagliptin plasma concentrations. - Excess alcohol: can potentiate metformin‑related lactic acidosis.